MX2022007630A - Combinaciones. - Google Patents
Combinaciones.Info
- Publication number
- MX2022007630A MX2022007630A MX2022007630A MX2022007630A MX2022007630A MX 2022007630 A MX2022007630 A MX 2022007630A MX 2022007630 A MX2022007630 A MX 2022007630A MX 2022007630 A MX2022007630 A MX 2022007630A MX 2022007630 A MX2022007630 A MX 2022007630A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- inhibitor
- disease
- treating
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940125944 selective estrogen receptor degrader Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Abstract
En la presente descripción se describen combinaciones de compuestos para tratar una enfermedad o afección, tal como el cáncer. Una combinación de compuestos para tratar una enfermedad o afección puede incluir un inhibidor de SERD y un inhibidor de Bcl-2, junto con sales farmacéuticamente aceptables de cualquiera de los anteriores.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962952056P | 2019-12-20 | 2019-12-20 | |
US202063004978P | 2020-04-03 | 2020-04-03 | |
US202063009916P | 2020-04-14 | 2020-04-14 | |
PCT/US2020/065398 WO2021127036A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022007630A true MX2022007630A (es) | 2022-08-16 |
Family
ID=76478148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022007630A MX2022007630A (es) | 2019-12-20 | 2020-12-16 | Combinaciones. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230054767A1 (es) |
EP (1) | EP4069236A4 (es) |
JP (1) | JP2023508324A (es) |
KR (1) | KR20220119418A (es) |
CN (1) | CN115023228A (es) |
AU (1) | AU2020407068A1 (es) |
BR (1) | BR112022012287A2 (es) |
CA (1) | CA3165341A1 (es) |
IL (1) | IL294067A (es) |
MX (1) | MX2022007630A (es) |
TW (1) | TW202135808A (es) |
WO (1) | WO2021127036A1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113717170A (zh) * | 2016-04-01 | 2021-11-30 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
CN111801327B (zh) * | 2018-01-10 | 2024-02-09 | 里科瑞尔姆Ip控股有限责任公司 | 苯甲酰胺化合物 |
-
2020
- 2020-12-16 IL IL294067A patent/IL294067A/en unknown
- 2020-12-16 KR KR1020227024699A patent/KR20220119418A/ko unknown
- 2020-12-16 JP JP2022538212A patent/JP2023508324A/ja active Pending
- 2020-12-16 BR BR112022012287A patent/BR112022012287A2/pt not_active Application Discontinuation
- 2020-12-16 CN CN202080094973.XA patent/CN115023228A/zh active Pending
- 2020-12-16 US US17/757,514 patent/US20230054767A1/en active Pending
- 2020-12-16 EP EP20903866.0A patent/EP4069236A4/en active Pending
- 2020-12-16 AU AU2020407068A patent/AU2020407068A1/en active Pending
- 2020-12-16 WO PCT/US2020/065398 patent/WO2021127036A1/en unknown
- 2020-12-16 CA CA3165341A patent/CA3165341A1/en active Pending
- 2020-12-16 MX MX2022007630A patent/MX2022007630A/es unknown
- 2020-12-18 TW TW109145125A patent/TW202135808A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN115023228A (zh) | 2022-09-06 |
EP4069236A1 (en) | 2022-10-12 |
IL294067A (en) | 2022-08-01 |
WO2021127036A1 (en) | 2021-06-24 |
JP2023508324A (ja) | 2023-03-02 |
EP4069236A4 (en) | 2023-12-27 |
US20230054767A1 (en) | 2023-02-23 |
BR112022012287A2 (pt) | 2022-08-30 |
AU2020407068A1 (en) | 2022-07-14 |
KR20220119418A (ko) | 2022-08-29 |
TW202135808A (zh) | 2021-10-01 |
CA3165341A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2019000263A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
MX2023000025A (es) | Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos. | |
MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
MX2022007626A (es) | Combinaciones. | |
MX2022007628A (es) | Combinaciones. | |
MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
MX2023008954A (es) | Inhibidores de los receptores erbb. | |
ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
PH12019502197A1 (en) | Macrocyclic compound and uses thereof | |
MX2021010321A (es) | Compuestos macrociclicos. | |
MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
MX2019003994A (es) | Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial. | |
WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
WO2019099646A8 (en) | Macrocyclic compounds and uses thereof | |
EA202092540A1 (ru) | Комбинации для лечения рака | |
ZA202206308B (en) | Ezetimibe and curcumin for use in cancer treatment | |
NZ733451A (en) | Combination therapy for pulmonary hypertension | |
MX2022007625A (es) | Combinaciones. | |
MX2022007623A (es) | Combinaciones. | |
EP3970793A4 (en) | AGENT FOR THE PREVENTION, APPEAL OR TREATMENT OF PERIODONTAL DISEASE | |
WO2020185651A3 (en) | Compositions and methods for treating huntington's disease | |
MX2021009717A (es) | Sulfonamidas biciclicas. |